BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 31360087)

  • 1. Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects.
    Trottier AM; Cerquozzi S; Owen CJ
    Blood Lymphat Cancer; 2017; 7():85-93. PubMed ID: 31360087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Jain A; Sweet K
    J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of blastic plasmacytoid dendritic cell neoplasm.
    Sullivan JM; Rizzieri DA
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):16-23. PubMed ID: 27913457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic literature review of 74 Chinese blastic plasmacytoid dendritic cell neoplasm patients.
    Gong C; Liu Y; Zhang M
    Ther Adv Hematol; 2024; 15():20406207241251602. PubMed ID: 38832237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
    Riaz W; Zhang L; Horna P; Sokol L
    Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
    Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
    Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.
    Nasiri A; Lami A; Alhumaidi A; Madkhali A; Althaqib A; Aljarwan N; Alkharras R
    Cureus; 2023 Apr; 15(4):e37016. PubMed ID: 37026111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological analysis of 46 cases with CD4
    Suzuki Y; Kato S; Kohno K; Satou A; Eladl AE; Asano N; Kono M; Kato Y; Taniwaki M; Akiyama M; Nakamura S
    Histopathology; 2017 Dec; 71(6):972-984. PubMed ID: 28795410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
    Song J; Li W; Bai Y; Zhou P; Niu J; Niu X; Liu Y; Liu X; Drokow EK; Sun K; Zhou H
    Ann Hematol; 2024 Feb; 103(2):463-473. PubMed ID: 38183444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CD123 in BPDCN: an emerging field.
    DiPippo AJ; Wilson NR; Pemmaraju N
    Expert Rev Hematol; 2021 Nov; 14(11):993-1004. PubMed ID: 34607517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Xue T; Budde LE
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):575-587. PubMed ID: 32336421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Kerr D; Zhang L; Sokol L
    Curr Treat Options Oncol; 2019 Feb; 20(1):9. PubMed ID: 30715612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.
    Kerr D; Sokol L
    Expert Opin Investig Drugs; 2018 Sep; 27(9):733-739. PubMed ID: 30118336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
    Adimora IJ; Wilson NR; Pemmaraju N
    Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review.
    Paluri R; Nabell L; Borak S; Peker D
    Hematol Oncol; 2015 Dec; 33(4):206-11. PubMed ID: 24850172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
    Economides MP; Konopleva M; Pemmaraju N
    Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
    Zanotta S; Galati D; De Filippi R; Pinto A
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
    Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.
    Beziat G; Ysebaert L
    Onco Targets Ther; 2020; 13():5199-5205. PubMed ID: 32606740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmacytoid dendritic cell neoplasms.
    Lee YJ; Kim Y; Park SH; Jo JC
    Blood Res; 2023 Apr; 58(S1):90-95. PubMed ID: 37105563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.